Legend Biotech has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026, succeeding Alan Bash, who served as Interim CEO. “Following a comprehensive search process, the Board concluded that Ingrid is the right leader to guide Legend Biotech through its next phase of growth,” said Frank Zhang, EMBA, PhD, Chairman of the Board. “As a highly respected industry executive, Ingrid brings strategic vision, operational discipline, and experience leading complex global businesses. The Board is confident she is well-positioned to advance our mission of transforming patient care through cell therapy.”
“Throughout this transition, our team has continued to execute against our strategic priorities with focus across the business,” said Alan Bash, President, CARVYKTI. “The commitment and expertise of colleagues around the world have positioned Legend Biotech for its next chapter. The leadership team and I look forward to partnering closely with Ingrid as we continue executing our strategy and delivering meaningful impact for patients.”
About Ingrid Zhang
Zhang brings more than two decades of global pharmaceutical leadership to the role. “It is a privilege to join Legend Biotech at an important moment in the Company’s growth,” said Ingrid Zhang, Chief Executive Officer of Legend Biotech. Legend Biotech has established itself as a global leader in cell therapy through its commitment to scientific innovation, operational excellence, and transforming outcomes for patients,” Zhang said. “I look forward to working with the talented team at Legend to build on this strong foundation, advance our pipeline, expand our impact, and execute on our long-term growth strategy.”
Zhang joins Legend Biotech from Novartis, where she spent 13 years, most recently as Chief Commercial Officer of Novartis International, driving commercial excellence, launch strategy, and portfolio decisions across the company’s international markets. She previously served as President and Managing Director of Novartis China and, before that, as President of Novartis Pharmaceuticals China, leading business development across the Chinese mainland and Hong Kong. Earlier in her Novartis career, she was Country Pharma Organization Head and Country President for Poland, and held business unit leadership roles in China spanning specialty care and primary care portfolios.
Before Novartis, Zhang spent six years at AstraZeneca, rising from Marketing Director in Milan to Business Unit Head of Oncology and CNS in China, and held a strategic planning and business development role at Pfizer. She began her career as a consultant at McKinsey & Company.
Zhang holds an MBA in Finance and Strategy from The Wharton School at the University of Pennsylvania, a master’s degree in Chemical Engineering from Penn State University, and a Bachelor of Arts in Chemistry from Lycoming College.
About Legend Biotech
With more than 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments for cancer care. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma that it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company and plans to drive future innovation across its pipeline of cell therapy modalities.
